Journal article Open Access

Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure

Laura Lorenzo-Soler; Ólöf B. Ólafsdóttir; Gerhard Garhöfer; Phatsawee Jansook; Íris Mýrdal Krístinsdóttir; Aimin Tan; Thorsteinn Loftsson; Einar Stefánsson


DCAT Export

<?xml version='1.0' encoding='utf-8'?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:adms="http://www.w3.org/ns/adms#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dct="http://purl.org/dc/terms/" xmlns:dctype="http://purl.org/dc/dcmitype/" xmlns:dcat="http://www.w3.org/ns/dcat#" xmlns:duv="http://www.w3.org/ns/duv#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:frapo="http://purl.org/cerif/frapo/" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:gsp="http://www.opengis.net/ont/geosparql#" xmlns:locn="http://www.w3.org/ns/locn#" xmlns:org="http://www.w3.org/ns/org#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:prov="http://www.w3.org/ns/prov#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:vcard="http://www.w3.org/2006/vcard/ns#" xmlns:wdrs="http://www.w3.org/2007/05/powder-s#">
  <rdf:Description rdf:about="https://zenodo.org/record/4561890">
    <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://zenodo.org/record/4561890</dct:identifier>
    <foaf:page rdf:resource="https://zenodo.org/record/4561890"/>
    <dct:creator>
      <rdf:Description rdf:about="http://orcid.org/0000-0002-2514-1323">
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#string">0000-0002-2514-1323</dct:identifier>
        <foaf:name>Laura Lorenzo-Soler</foaf:name>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>University of Iceland</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Ólöf B. Ólafsdóttir</foaf:name>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>University of Iceland</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Gerhard Garhöfer</foaf:name>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>Medical University of Vienna</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Phatsawee Jansook</foaf:name>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>Chulalongkorn University</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Íris Mýrdal Krístinsdóttir</foaf:name>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>Oculis ehf.</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Aimin Tan</foaf:name>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>Nucro-Technics</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Thorsteinn Loftsson</foaf:name>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>University of Iceland</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Einar Stefánsson</foaf:name>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>University of Iceland</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:title>Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure</dct:title>
    <dct:publisher>
      <foaf:Agent>
        <foaf:name>Zenodo</foaf:name>
      </foaf:Agent>
    </dct:publisher>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#gYear">2020</dct:issued>
    <dcat:keyword>angiotensin receptor blockers</dcat:keyword>
    <dcat:keyword>intraocular pressure</dcat:keyword>
    <dcat:keyword>cyclodextrins</dcat:keyword>
    <dcat:keyword>pharmacokinetics</dcat:keyword>
    <frapo:isFundedBy rdf:resource="info:eu-repo/grantAgreement/EC/H2020/765441/"/>
    <schema:funder>
      <foaf:Organization>
        <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10.13039/501100000780</dct:identifier>
        <foaf:name>European Commission</foaf:name>
      </foaf:Organization>
    </schema:funder>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#date">2020-11-16</dct:issued>
    <owl:sameAs rdf:resource="https://doi.org/10.1111/aos.14639"/>
    <adms:identifier>
      <adms:Identifier>
        <skos:notation rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://doi.org/10.1111/aos.14639</skos:notation>
        <adms:schemeAgency>doi</adms:schemeAgency>
      </adms:Identifier>
    </adms:identifier>
    <owl:sameAs rdf:resource="http://www.ncbi.nlm.nih.gov/pubmed/33191620"/>
    <adms:identifier>
      <adms:Identifier>
        <skos:notation rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">http://www.ncbi.nlm.nih.gov/pubmed/33191620</skos:notation>
        <adms:schemeAgency>pmid</adms:schemeAgency>
      </adms:Identifier>
    </adms:identifier>
    <owl:sameAs rdf:resource="https://zenodo.org/record/4561890"/>
    <adms:identifier>
      <adms:Identifier>
        <skos:notation rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://zenodo.org/record/4561890</skos:notation>
        <adms:schemeAgency>url</adms:schemeAgency>
      </adms:Identifier>
    </adms:identifier>
    <owl:sameAs rdf:resource="https://doi.org/10.1111/aos.14639"/>
    <dct:description>&lt;p&gt;Orally administered angiotensin II receptor blockers (ARBs) decrease intraocular pressure (IOP). Topical administration may reduce systemic side effects and result in a useful glaucoma drug. The aim of this study is to test the ocular delivery and pharmacologic effect of nanoparticle eye drops containing ARBs (e.g. irbesartan and candesartan).&lt;br&gt; 1.5% irbesartan and 0.15% candesartan eye drops were applied to rabbits. The pharmacokinetics in cornea and aqueous humour after single eye drop application were studied in 49 rabbits. The effect of the eye drops on IOP was studied in 10 rabbits using an iCare ( TonoVet Plus, iCare, Finland) tonometer and compared with 0.5% timolol eye drops.&lt;br&gt; Candesartan lowered IOP from 24.6 &amp;plusmn; 5.1 mmHg at baseline to 19.0 &amp;plusmn; 2.9 mmHg (mean &amp;plusmn; SD, p = 0.030, n = 10) 4 hr after application.&lt;br&gt; Irbesartan lowered IOP from 24.2 &amp;plusmn; 1.7 mmHg to 20.2 &amp;plusmn; 0.9 mmHg (p = 0.14, n = 10). Timolol decreased the IOP from 24.9 &amp;plusmn; 4.2 mmHg to 20.4 &amp;plusmn; 4.8 mmHg (mean &amp;plusmn; SD, p = 0.036, n = 10). The pharmacokinetics data show that both formulations deliver effective amounts of drug into the intraocular tissues, with irbesartan and candesartan reaching concentrations of 121&amp;plusmn; 69 and 30.43 &amp;plusmn; 13.93 ng/g (mean &amp;plusmn; SD), respectively, in the aqueous humour 3 hr after a single-dose administration.&lt;br&gt; Topical application of irbesartan and candesartan eye drops delivers effective drug concentrations to the anterior segment of the eye in rabbits, achieving drug concentrations 100 times above the IC50 for angiotensin II receptor and showing an IOP-lowering effect. Angiotensin receptor blocker (ARB) eye drops have potential as a new class of glaucoma drugs.&lt;/p&gt;</dct:description>
    <dct:accessRights rdf:resource="http://publications.europa.eu/resource/authority/access-right/PUBLIC"/>
    <dct:accessRights>
      <dct:RightsStatement rdf:about="info:eu-repo/semantics/openAccess">
        <rdfs:label>Open Access</rdfs:label>
      </dct:RightsStatement>
    </dct:accessRights>
    <dct:license rdf:resource="https://creativecommons.org/licenses/by/4.0/legalcode"/>
    <dcat:distribution>
      <dcat:Distribution>
        <dcat:accessURL rdf:resource="https://doi.org/10.1111/aos.14639">https://doi.org/10.1111/aos.14639</dcat:accessURL>
        <dcat:byteSize>263323</dcat:byteSize>
        <dcat:downloadURL rdf:resource="https://zenodo.org/record/4561890/files/aos.14639.pdf">https://zenodo.org/record/4561890/files/aos.14639.pdf</dcat:downloadURL>
        <dcat:mediaType>application/pdf</dcat:mediaType>
      </dcat:Distribution>
    </dcat:distribution>
  </rdf:Description>
  <foaf:Project rdf:about="info:eu-repo/grantAgreement/EC/H2020/765441/">
    <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#string">765441</dct:identifier>
    <dct:title>Educating the next generation of scientists in translational medicine: Focus on eye diseases</dct:title>
    <frapo:isAwardedBy>
      <foaf:Organization>
        <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10.13039/501100000780</dct:identifier>
        <foaf:name>European Commission</foaf:name>
      </foaf:Organization>
    </frapo:isAwardedBy>
  </foaf:Project>
</rdf:RDF>
9
56
views
downloads
Views 9
Downloads 56
Data volume 14.7 MB
Unique views 6
Unique downloads 54

Share

Cite as